A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
Esophageal Squamous Cell Carcinoma
BIOLOGICAL: OCDC vaccine; NeoDC vaccine
The number of treatment-related adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, From the first administration of vaccine to 3 months after the last administration
Disease-free Survival, Number of participants with Disease-free Survival as assessed by RECIST1.1, from the study start to 1 year after the study completion
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC